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Abstract
Background: Breast cancer (BC) immune infiltrates play a critical role in tumor progression and response to treatment.
Besides stromal tumor infiltrating lymphocytes (sTILs) which have recently reached level 1B evidence as a prognostic
marker in triple negative BC, a plethora of methods to assess immune infiltration exists, and it is unclear how these
compare to each other and if they can be used interchangeably.
Methods: Two experienced pathologists scored sTIL, intra-tumoral TIL (itTIL), and 6 immune cell types (CD3+, CD4+,
CD8+, CD20+, CD68+, FOXP3+) in the International Cancer Genomics Consortium breast cancer cohort using
hematoxylin and eosin-stained (n = 243) and immunohistochemistry-stained tissue microarrays (n = 254) and whole
slides (n = 82). The same traits were evaluated using transcriptomic- and methylomic-based deconvolution methods or
signatures.
Results: The concordance correlation coefficient (CCC) between pathologists for sTIL was very good (0.84) and for cell-
specific immune infiltrates slightly lower (0.63–0.66). Comparison between tissue microarray and whole slide pathology
scores revealed systematically higher values in whole slides (ratio 2.60–5.98). The Spearman correlations
between microscopic sTIL and transcriptomic- or methylomic-based assessment of immune infiltrates were
highly variable (r = 0.01–0.56). Similar observations were made for cell type-specific quantifications (r = 0.001–
0.54). We observed a strong inter-method variability between the omics-derived estimations, which is further
cell type dependent. Finally, we demonstrated that most methods more accurately identify highly infiltrated
(sTIL ≥ 60%; area under the curve, AUC, 0.64–0.99) as compared to lowly infiltrated tumors (sTIL ≤ 10%; AUC
0.52–0.82).
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Conclusions: There is a lower inter-pathologist concordance for cell-specific quantification as compared to
overall infiltration quantification. Microscopic assessments are underestimated when considering small cores
(tissue microarray) instead of whole slides. Results further highlight considerable differences between the
microscopic-, transcriptomic-, and methylomic-based methods in the assessment of overall and cell-specific
immune infiltration in BC. We therefore call for extreme caution when assessing immune infiltrates using
current methods and emphasize the need for standardized immune characterization beyond TIL.
Keywords: Immune infiltrate, Breast cancer, Benchmarking, Methodology, Tumor infiltrating lymphocytes,
Transcriptome, Methylome, Microscopy, Digital pathology
Background
In breast cancer (BC), the presence of immune infiltrate
and its composition affects prognosis and treatment effi-
cacy, including response to novel immunotherapies [1–5].
Specifically, increased levels of stromal tumor infiltrating
lymphocytes (sTILs) are associated with response to neo-
adjuvant chemotherapy and prognosis in triple negative
BC (TNBC) patients [4, 6–11]. In this context, sTIL has
now been recognized as a valid prognostic biomarker by
the expert panel of the 16th St. Gallen Breast Cancer Con-
ference. Clinical trials investigating immunotherapies in
BC are also using TIL or CD8+ T cell scores either for
screening patients (e.g., NCT02997995) or as an endpoint
(e.g., NCT03875573, NCT03815890, NCT03395899). Reli-
able methods to estimate the amount and composition of
the immune infiltrate are therefore critical, for cross-study
comparisons and future biomarker development.
Over the past years, several waves of technology have
advanced the quantification and characterization of the
immune infiltrate in solid tumors. Pathologists have de-
veloped methods to study the immune composition
through the microscope [12, 13], while advances in com-
putational biology have enabled the inference of cell type
composition of solid tumors by utilizing bulk transcrip-
tomic and methylomic data [14]. Currently, these
methods are often used interchangeably in translational
and fundamental research, assuming that they are pro-
viding similar information. However, the different
methods do have different properties and it may be chal-
lenging to directly compare methods because of this. To
the best of our knowledge, a detailed comprehensive
comparison of these methods, including cell type infer-
ence using pathology, is still missing in BC, partly due to
the lack of centralized microscopic, transcriptomic, and
methylomic data.
The primary objective of the current study was therefore
to compare the estimations of overall and cell-specific im-
mune infiltration obtained by microscopic, transcriptomic,
and methylomic methods in the International Cancer
Genomics Consortium (ICGC) BC cohort [15–17]. The
secondary objective was to evaluate the reliability of the
different methods to classify tumors as highly or poorly
infiltrated [10], as stratification of patients according to se-
verity of sTIL infiltration has proven prognostic import-
ance and may become a clinical biomarker in the near
future [4, 10, 18].
Methods
Patients and dataset
This study is established on the ICGC BC cohort (https://
dcc.icgc.org/) including 548 primary samples of female pa-
tients, for whom transcriptomic and methylomic data
were available for 257 and 318 patients, respectively [15].
Data access was granted by ICGC. The generated path-
ology data, the type of data available for each patient, and
the distribution of clinical and pathological characteristics
are available at https://doi.org/https://doi.org/10.6084/m9.
figshare.8234246.
Quantification of the tumor immune infiltrate
We collected tissue microarrays (TMAs; 3 cores/tumor,
n = 254), whole slides (WS) for IHC (n = 82), and
hematoxylin and eosin-stained WS (H&E; n = 243).
TMAs and WS were stained for CD3, CD4, CD8, CD20,
CD68, and FOXP3. Specific antibody clones, dilutions,
and incubation times are listed in Additional file 1:
Table S1. H&E slides were used to assess stromal TIL
(sTIL) and intra-tumoral TIL (itTIL) for the whole slides
and the TMAs. Two experienced pathologists (RS,
HMH) scored all slides using the online pathology plat-
form Slidescore [19] and reported the percentage of
positive immune cells in the stromal and intra-tumoral
compartment for each H&E- or IHC-stained slide, ac-
cording to the existing guidelines [13]. A two-step digital
image analysis (DIA) was performed using the Visio-
pharm Integrator System Software (VIS; Visiopharm A/
S, Hoersholm, Denmark) using two optimized applica-
tions within the software to recognize positive DAB
staining and tissue versus non-tissue. First, an applica-
tion was used to detect the tissue and remove artifacts.
With the second application, the positive-stained area
(IHC-stained) was detected and the output variable is
the positive area. Detection of, for example, CD3 positiv-
ity is based on the HDAB-DAB color deconvolution
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band. For all samples, the same threshold of positivity
was kept.
For the computational analysis, we included methods
that provided an estimation of the immune infiltration
with respect to the entire tumor (Table 1, Add-
itional file 1: Table S2). This list includes techniques
used regularly for cell type inference. It should not been
seen as exhaustive as new techniques are constantly be-
ing developed. We have included methods based on
gene expression and methylation profiles, as both allow
to study sample composition. Methods that estimate cel-
lular populations from bulk data can be bluntly divided
into two categories:
(1) Those based on marker genes, providing an
independent (semi-quantitative) assessment for
each cell type, enabling comparison between
samples but not within samples
(2) Those based on deconvolution algorithms, inferring
cell type fractions, enabling comparison between
and within samples [14, 30]
To provide potential validation for immune infiltration,
we calculated gene signatures specific for immune cell ac-
tivity, namely cytolytic activity (CytAct) and interferon-
gamma (IFNg) [31, 32]. All fractions of TIL and cell popu-
lations for each method are available at https://doi.org/
https://doi.org/10.6084/m9.figshare.8234246.
Details for each method and processing are available
in Additional file 1, which also includes Additional file 1:
Tables S2 and S3.
Statistical analysis
Statistical analyses were performed using R version 3.5.1.
Values for immune infiltration were log transformed
with an offset of 0.05. The agreement between observers
and methods was assessed using the Bland-Altman
method and Passing-Bablok regression analyses. Specif-
ically, the geometric mean of the two scores from the
same stained tumor section (x axis) is plotted against the
ratio between the two methods or observers (y axis),
considering the overall geometric mean of the ratios
(center line) and the approximate 95% limits of agree-
ment (horizontal lines), and Loess fitted curves were
incorporated. Analysis was performed on all samples
with available information for the methods taken into
consideration. The concordance correlation coefficient
(CCC) was used as a summary measure of reproducibil-
ity between observations [33] for each cell type. To es-
tablish the contribution of the itTIL and sTIL values to
all TIL, a combined “averaged” TIL score was calculated
by taking the arithmetic mean of the sTIL and itTIL
scores for each sample and the Passing-Bablok regres-
sion was used for the comparison between TIL scores.
To assess replicability, correlations between methods
for tumor immune infiltration were measured using the
non-parametric Spearman’s rho coefficient, and a Loess
smoothing was used for flexible interpolation. The 95%
confidence intervals (CI) were calculated using the boot-
strapping procedure with 1000 bootstrap samples (over-
lapping the results from the asymptotic approximation).
Both the Spearman’s rho coefficient and Linn’s CCC
were interpreted according to qualifiers as “very poor”
Table 1 Computational and microscopic methods used for estimation of overall infiltration and calculation of specific cell
populations
Method Approach Description Overall immune score Cell populations
H&E whole slide (WS) Microscopy based Pathology TIL scores TIL scores NA
IHC whole slide (WS) Microscopy based Pathology scores with IHC Summed lymphocyte fractions Yes
Whole slide digital (digWS) Microscopy based Visiopharm digital scores IHC NA Yes
H&E tissue microarray (TMA) Microscopy based Pathology TIL scores TIL scores NA
IHC tissue microarray (TMA) Microscopy based Pathology scores IHC Summed lymphocyte fractions Yes
TMA digital (digTMA) Microscopy based Visiopharm digital scores IHC Summed lymphocyte fractions Yes
Absolute CIBERSORT (aCBS) [20] Deconvolution Cell fractions, absolute mode used Summed lymphocyte fractions Yes
quanTIseq, lsfit (qSEQ) [21] Deconvolution Cell fractions, absolute Summed lymphocyte fractions Yes
MCP-counter (MCP) [22] Gene marker Arbitrary units NA Yes
xCell [23] Gene marker Arbitrary units NA Yes
EPIC [24] Deconvolution Cell fractions, absolute Summed lymphocyte fractions Yes
MethylCIBERSORT (metCBS) [25] Deconvolution Cell fractions, absolute Summed lymphocyte fractions Yes
TIL rna score (TILrna) [26] Gene marker TIL associated gene signature TIL signature NA
meTIL [27] Gene marker TIL methylation profile TIL signature NA
Cell signatures Davoli et al. [28] Gene marker Computed gene signature NA Yes
Cell signatures Danaher et al. [29] Gene marker Computed gene signature NA Yes
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(< 0.20), “poor” (0.20–0.40), “moderate” (0.40–0.60),
“good” (0.60–0.80), and “very good” (0.80–1.00) [34].
To distinguish the highly and poorly infiltrated tu-
mors, the (calculated) overall immune infiltration
value (available at https://doi.org/https://doi.org/10.
6084/m9.figshare.8234246) from each method was uti-
lized. The thresholds used for the categorization are
based on the published meta-analysis on BC infiltra-
tion [10]: sTIL ≤ 10% for poorly infiltrated tumors,
11–59% for intermediately infiltrated tumors, and ≥
60% for highly infiltrated tumors. To evaluate if
different methods would classify the same tumor as
poorly or highly infiltrated, receiver operator charac-
teristic curves were generated and area under the
curves (AUCs) of each classifier were calculated using
pROC package version 1.13.0. All tests were two-
sided.
Results
Assessment of immune cells on H&E and IHC whole slides
Two experienced pathologists scored itTIL, sTIL, and six im-
mune cell types (CD3+, CD4+, CD8+, CD20+, CD68+,
FOXP3+) in an invasive primary BC cohort [15]. In line with
previous reports [35–39], we observed a very good inter-
observer CCC both for sTIL and itTIL (0.84 and 0.85, re-
spectively, Fig. 1a). The limits of agreement showed a fair
relative precision between measurements, and no major con-
stant (intercept) or proportional (slope) drift between the
two pathologists (Additional file 1: Figure S1). A very good
concordance was observed between the stromal and aver-
aged TIL (CCC 0.84, Fig. 1b), while by contrast, a poor con-
cordance was observed between the intra-tumoral and
averaged TIL score (CCC 0.37, Fig. 1c). These results show
that immune infiltration in BC is mainly localized in the stro-
mal compartment and is not greatly interfered by intra-
Fig. 1 Reliability of standard microscopic pathology and digital analysis to estimate the immune composition. a Forest plots representing estimated
concordance correlation coefficients with 95% confidence interval (CI) for each pairing between pathologists (inter-observer agreement) on H&E and whole
slides (WS). CCC (95% CI): sTIL, 0.84 (0.79–0.87); itTIL, 0.85 (0.81–0.88); sCD3, 0.64 (0.49–0.75); itCD3, 0.64 (0.50–0.75); sCD4, 0.63 (0.48–0.75); itCD4, 0.42 (0.22–0.59);
sCD8, 0.66 (0.52–0.76); itCD8, 0.53 (0.37–0.67); sCD20, 0.66 (0.52–0.76); itCD20, 0.43 (0.27–0.56); sFOXP3, 0.65 (0.50–0.76); and itFOXP3, 0.48 (0.32–0.62). Cohen’s K
for the macrophages staining (CD68) based on 4 infiltration categories (nil, mild, moderate, and severe). b The Passing-Bablok regression between the averaged
(averaged sTIL and itTIL) TIL and sTIL (r=0.84). c The Passing-Bablok regression between the global TIL and itTIL (r=0.37). d The Bland-Altman analysis of the
CD3 score agreement between TMA and WS. e The Bland-Altman analysis for agreement between CD3 whole slide digital pathology and CD3 TMA digital
pathology. f The Passing-Bablok between CD3 assessment by pathologists and digital pathology
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tumoral infiltration. Of note, some tumors with a high over-
all infiltration could still lack itTIL, as depicted in Fig. 1c, and
include most probably tumors where the immune infiltrate is
restricted to the stroma or to the tumor margin. The inter-
observer analysis demonstrated a moderate CCC for the im-
munohistochemical (IHC) assessments, where stromal scor-
ing performed overall better and more precisely than intra-
tumoral scoring (Fig. 1a). All stromal IHC CCC values were
lower for immune cell subtypes than for sTIL and itTIL as-
sessment on H&E, ranging from 0.63 to 0.66 (Fig. 1a). The
intra-tumoral IHC methods had a CCC below 0.6, except for
itCD3 (CCC= 0.64). We therefore only considered the more
reliable and abundant stromal estimates for further analyses.
Comparison of tumor immune infiltration estimates
between tissue microarrays and whole slides (H&E and IHC)
When stromal TIL was scored on both whole H&E slides
and TMA H&E, the correlation was moderate (0.56) (Fig. 3).
The CCC between WS and TMA was only 0.26, where over-
all a lower (5.98× lower) percentage was scored on H&E
TMAs compared to whole H&E slides (Additional file 1: Fig-
ure S2a). We characterized six immune features both on
TMA and WS (Fig. 2a). The immune infiltrate scores were
systemically higher on WS as compared to TMA, as depicted
in Fig. 1d for the most abundant immune cell population,
i.e., CD3+, and in Additional file 1: Figure S2a for the other
immune cells. The CCCs between WS and TMA were glo-
bally poor and ranged between 0.21 for CD4+ and 0.43 for
FOXP3+ cells (Additional file 1: Figure S2b). We further eval-
uated both TMA and WS using digital pathology and con-
firmed the higher level of immune infiltration estimated with
WS as compared to TMA (Fig. 1e, Additional file 1: Figure
S2c), highlighting the spatial heterogeneity of the tumor im-
mune microenvironment (Additional file 1: Figure S2b). Fig-
ure 2b depicts one sample that shows high infiltration on the
WS and limited infiltration in the TMA. In line with previ-
ous reports [35], we observed a moderate correlation be-
tween human and digital assessment of CD3+ (CCC= 0.42,
Fig. 1f), yet the digital evaluation showed a lower estimation
of all immune cells compared to pathologists
Fig. 2 Immunohistochemical assessment of immune cells. a Immunohistochemical staining for 6 immune markers and the hematoxylin and
eosin-stained corresponding tissue microarray (TMA) core. b Whole slide and corresponding TMAs, stained for CD3, for patient PD13760
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(Additional file 1: Figure S2d,), suggesting a relative human
overestimation or digital underestimation of tumor immune
infiltration.
Comparison of microscopic, transcriptomic, and
methylomic evaluation of overall tumor immune
infiltration
To evaluate if different data types could estimate overall
immune infiltration consistently, we compared the (calcu-
lated) score of several microscopic-, transcriptomic-, and
methylomic-based methods. In addition, two inflammatory
gene signatures (interferon-gamma and cytolytic activity)
were calculated (pink category in Fig. 3), as these often cor-
relate to tumor immune infiltration and can provide infor-
mation on the status of the tumor microenvironment [31,
32]. A description of all methods is provided in Table 1 and
Additional file 1: Table S2. First, while the Spearman correla-
tions between microscopic (red) and all methylomic (blue)
or transcriptomic (green) estimates were poor to moderate,
our analysis showed that stromal infiltration correlates better
Fig. 3 Methods to assess overall infiltration. a Matrix plot of Spearman’s correlations for the methods providing information on overall immune
infiltration; tumor infiltrating lymphocytes (TILs) or the sum of T cells and B cells was taken to derive a TIL fraction. b Matrix plot for Spearman’s
correlations of the methods providing information on overall immune infiltration in ER-positive tumors and c ER-negative tumors. aCBS, absolute
CIBERSORT [20]; digTMA, tissue microarray scored by Visiopharm (digital analysis); MCP, MCP-counter [22]; meTIL, methylation TIL score [27];
metCBS, methylCIBERSORT [25]; itTIL, intra-tumoral TIL on H&E; qSEQ, quanTIseq [21]; sTIL, stromal TIL on H&E; TILrna, TIL score based on transcriptome
[26]; TMA (H&E), sTIL scored on TMA; TMA (IHC), tissue microarray scored by pathologists with CD3 and CD20 markers to calculate the sTIL; WS (IHC),
whole slide immunohistochemistry of CD3 and CD20 by pathologists
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with all other methods, including transcriptomic and methy-
lomic methods, as compared to the intra-tumoral infiltration
(Fig. 3a). We tested the possibility that higher itTIL may lead
to more pronounced inflammatory gene expression than
sTIL as itTIL may have a crucial anti-tumor role [40–44].
Yet, we observed no higher correlation between intra-
tumoral infiltration and inflammation-associated signatures
(immune signatures, pink label Fig. 3a). Secondly, a good cor-
relation was observed between stromal microscopy assess-
ment on H&E-stained (sTIL) and IHC-stained WS, where
the sum of T (CD3+) and B (CD20+) cells were considered
(r= 0.61). Thirdly, the correlation with the immune gene sig-
natures, cytolytic activity (r= 0.51) and IFNg (r= 0.57), im-
proved slightly when the infiltrate was scored with digital
pathology compared to the other microscopic (red) methods
(Fig. 3a). This is most probably because both the immune
signatures (CytAct and IFNg) and the digital assessment of
the TMA do not consider the type of infiltrates (intra-tu-
moral vs stromal). The same trend was observed between
the digital assessment of the TIL on TMA (digTMA) and
transcriptomic TIL methods (green), where the Spearman
correlations with EPIC (r= 0.42), aCBS (r= 0.53), and TILrna
(r= 0.56) were again the highest compared to all other
microscopic (red) methods. Fourthly, as expected, methods
using the same modality for input of data showed better cor-
relations. For example, several transcriptomic estimates
showed a very good correlation with each other (r >
0.80), and methylCIBERSORT [25] and the methylo-
mic TIL score, meTIL [27], showed a reassuring good
agreement (r = 0.77). The correlation between tran-
scriptomic and methylomics was variable, but methyl-
CIBERSORT showed good correlations with absolute
CIBERSORT (r = 0.75) and TILrna [26] (r = 0.76), and
similar observations could be made for meTIL and
CIBERSORT(r = 0.66) and meTIL and TILrna (r =
0.70). Fifthly, of the transcriptomic and methylomic
methods, TILrna, methylCIBERSORT, and absolute
CIBERSORT [20] showed the highest correlations
with microscopy scores, though the correlations were
still not perfect with the highest being 0.56 between
digTMA and TILrna, 0.53 considering sTIL and
methylCIBERSORT, and 0.53 between digTMA and
absolute CIBERSORT. These numbers were however
in line with a recently published lung cancer study
[45]. Finally, of the methods that predict global im-
mune infiltration based on the transcriptome (green
label in Fig. 3a), TILrna showed the highest correla-
tions with the various immune gene signatures (pink
label, r = 0.90–0.94), while quanTIseq [21] showed the
poorest correlations (r = 0.16–0.18). Similar analyses
were further carried on separately for ER-negative
and ER-positive tumors as the biological significance
of the immune infiltrate may be different [46, 47]
(Fig. 3b, c). The correlations for the microscopic-
versus methylomic- and transcriptomic-based methods
were in general slightly higher in the ER-negative
compared to the ER-positive subgroup. Nevertheless,
compared to all samples, the ER-negative tumors did
not necessarily show higher correlations.
Following the analysis at the continuous level (Fig. 3a–
c), we further aimed to investigate the ability of the
methods to identify lowly infiltrated (sTIL ≤ 10%) and
highly infiltrated (sTIL ≥ 60%) tumors as defined by Den-
kert and colleagues [10]. TIL is currently not used as a
classifier in the clinic, yet the stratification of patients
based on TIL has provided important prognostic informa-
tion in clinical studies [4, 18]. To this end, a ROC curve
analysis was performed (Fig. 4a, b) and most methods per-
formed moderate to very poor in recognizing the lowly in-
filtrated tumors (Fig. 4a, c blue boxes). The itTIL score
showed the highest area AUC for the lowly infiltrated tu-
mors (Fig. 4c, blue boxes), and the methylomic-based TIL
scores had a slightly higher AUC as compared to the
transcriptomic-based methods, although their confidence
intervals were overlapping. ROC analyses further showed
that most methods can more accurately identify highly in-
filtrated tumors as compared to lowly infiltrated tumors
(Fig. 4b, c red boxes). Here, the highest AUCs were still
based on the microscopy methods, but methylomic- and
transcriptomic-based methods also showed fair to high
AUCs. Of interest, highly infiltrated tumors have the high-
est expression of inflammatory signatures, like interferon-
gamma and cytolytic activity (Fig. 4d), yet lowly infiltrated
tumors could also show a wide range of these inflamma-
tory gene expressions.
Comparison of microscopic, transcriptomic, and
methylomic evaluation of cell-specific immune infiltration
Several observations could be made from the compari-
son between microscopic and computational methods
that quantify specific immune cell types with transcrip-
tomic or methylomic data (Table 1, Fig. 5a–e). Firstly,
the correlations between the microscopic evaluations
and the transcriptomic and methylomic data were always
< 0.60, with CD8+ T cells showing the highest (Fig. 5a)
and macrophages (Fig. 5e) the lowest correlation be-
tween microscopic and methylomic or transcriptomic
methods, respectively. Of interest, there was no system-
atic increase in the correlation coefficients when consid-
ering WS instead of TMA scores. Of note, when we
examined the CCC between methods for specific cell
types, poor concordance (< 0.3) was found for all
methods (data not shown). Secondly, most omics-
derived methods showed large inconsistencies between
cell types regarding their correlation with microscopy.
For example, while quanTIseq showed very poor correl-
ation with sTIL (0.09; Fig. 3a) and CD4+ cells (0.01, WS
evaluation; Fig. 5b), the correlations for CD8+ were
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moderate (0.54, WS evaluation, Fig. 5a). Altogether,
these analyses highlight the variable correlation between
the different omics-derived methods and microscopic as-
sessments, which further vary according to the immune
cell type.
Discussion
In this study, we have comprehensively demonstrated
that methods of the same modality (microscopy, tran-
scriptomic, or methylomic based) to estimate overall
infiltration show reassuring correlations, but the correla-
tions deteriorate when comparing between modalities.
In addition, we quantified specific immune cell types
and observed a strong heterogeneity in the correlations
between the microscopic- and omics-based estimates,
and also between the different omics-based estimates.
For each cell type, the best method to use may be differ-
ent. Our analysis clearly shows that different transcrip-
tomic and methylomic methods have limitations in
estimating immune infiltration, as correlations with
Fig. 4 Identifying lowly and highly infiltrated tumors. The ROC curves for the different TIL methods a to classify lowly infiltrated tumors compared to the rest
(blue color) and b to classify highly infiltrated tumors compared to rest (red color). The corresponding AUCs from a (blue color) and b (red color) are depicted in
c. The distribution of TIL scores for the TIL methods and inflammatory signatures—cytolytic activity and interferon-gamma—is depicted in d for the low (≤ 10%),
medium (11–59%), and high (≥ 60%) infiltrated tumors according to stromal TIL scores
Nederlof et al. Breast Cancer Research          (2019) 21:151 Page 8 of 13
microscopy-based methods do not exceed 0.6. As the path-
ology assessment of TIL has reached level 1B evidence with
new studies confirming its value for the patient [4], the fact
that correlations are not high may warrant extra caution
when using non-pathology methods as these may measure
different characteristics of the immune infiltrate. These find-
ings might be explained by the fact that transcriptomic and
methylomic data are not perfectly representing protein ex-
pression of immune cells. In addition, regular bulk transcrip-
tome or methylome analysis does not detect heterogeneity
within a sample and ignores the localization of cells [48]. An
example as depicted in Fig. 2b emphasizes the importance of
spatial heterogeneity, but also raises the question about the
functionality of the observed immune infiltrate. Importantly,
Fig. 5 Methods to assess cell-specific infiltration. Spearman’s correlation plots for CD8 T cells (a), CD4 T cells (b), regulatory T cells (Tregs) (c), B cells (d),
and macrophages (e). aCBS, absolute CIBERSORT [20]; digTMA, tissue microarray scored by Visiopharm (digital analysis); MCP, MCP-counter [22]; meTIL,
methyl TIL score [27]; metCBS, methylCIBERSORT [25]; itTIL, intra-tumoral TIL on H&E; qSEQ, quanTIseq [21]; sTIL, stromal TIL on H&E; TILrna, TIL score
based on transcriptome [26]; TMA IHC, tissue microarray scored by pathologists; WS IHC, whole slide immunohistochemistry by pathologists
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transcriptomic or methylomic methods may be biased to-
wards a specific cell state, as they are often based on cells
challenged with experimental processes (e.g., tissue digestion
or flow cytometry) or from different origin (e.g., peripheral
blood or different tumors), which may contribute to the ob-
served discordance with microscopy.
More research into the contribution and spatial distribu-
tion of specific immune cells in the context of clinical out-
come is warranted to understand beneficial and detrimental
immune cell profiles. Spatially resolved methods, measuring
genetic and phenotypic diversity, would support advances for
clinical studies [49]. Moreover, integration of deep learning
approaches with morphological features, in conjunction with
genomic-derived data, will probably be needed to derive a
full comprehensive evaluation of the immune environment
in solid tumors. Our data provided us with insightful obser-
vations that can guide future research using digital image
analysis. First, we showed that stromal evaluation of several
immune cell types is reliable with an acceptable concordance
observed between pathologists, especially for stromal infiltra-
tion. Second, values may also be estimated with a digital ap-
proach, taking into account the systematically lower
numerical values for digital estimates [35]. Third, our results
raise caution for the evaluation of immune markers on TMA
(or biopsies) as small punches of the tumor may obscure in-
formation of infiltration and WS showed overall a higher in-
filtration than TMA. Our results on immune infiltrate are in
contrast with several studies which demonstrated that TMAs
are reliable for the evaluation of several prognostic epithelial-
based tumor markers [50–53].
Our second objective was to stratify patients into lowly in-
filtrated and highly infiltrated tumors, as more clinical studies
showed that sTIL-based stratification could serve as an im-
portant prognosticator [4, 18]. We observed that microscopic
methods (itTIL, WS, TMA IHC, digTMA) were better in the
stratification of patients into lowly or highly infiltrates, as ex-
pected due to their common modality as sTIL (as opposed
to, for example, gene expression-based methods). We also
showed here that the majority of the methods are better in
recognizing highly infiltrated tumors as compared to lowly
infiltrated tumors. The lower accuracy for identification of
lowly infiltrated tumors may be problematic as the majority
of the breast tumors will have infiltration above 0% but far
below 60%, as shown by Loi et al. [4] in early TNBC. These
findings should be taken into consideration in developing in-
clusion and stratification criteria, as well as endpoints in the
context of clinical trials.
Strengths of this study include the large number of pa-
tients and extensive central evaluation of immune cells,
together with the availability of transcriptomic and
methylomic data. A limitation of our study is that tissue
analysis (FFPE) and DNA/RNA isolation (FF) were not
performed on the exact same area from the tumor. Infil-
tration may be affected by heterogeneity and partially
explain the correlations not exceeding 0.6. We mini-
mized this effect by studying multiple cores spread
throughout the tumor in the TMA and large sections of
the tumors in WS, far exceeding the area usually evalu-
ated with biopsies. Nevertheless, correlation with various
omics-based methods did not systematically increase
when considering WS versus TMA. In addition, the
digital analyses of the immune cells were calculated as
an area, while pathologists report a cellular percentage,
leading to pre-analytical factors that affect the results.
We were however not able to calculate the cellular per-
centage due to visual cell segmentation problems. An-
other limitation is that the omics-based methods
considered in this manuscript do not consider the
localization of the cells in the tumors. In this context, a
recent study conducted in TNBC suggested that tran-
scriptomics might have the potential to derive this
spatial information [54]. Finally, this cohort does not
provide follow-up or therapy response data. Future stud-
ies may test superiority of specific measures with the ul-
timate goal to better guide precision medicine.
Conclusion
This study highlights an important heterogeneity in the vari-
ous estimates of immune infiltrates in BC and calls for cau-
tion when used in the clinical context. This study further
provides an important resource of multi-level data of the
tumor immune microenvironment to researchers for future
investigations. Ultimately, there is an urgent need for the de-
velopment of international guidelines to categorize breast tu-
mors according to their immune infiltrate in both a
quantitative and a qualitative manner. Combining the valu-
able information from multiple methods, e.g., the spatial in-
formation from pathology and transcriptomic information
on cellular activity, may elucidate the role of immune infiltra-
tion in disease progression in a more accurate manner.
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